Age-Related Macular Degeneration Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report Download FREE Resources

Published: December 22, 2025 Report Code: GDHC328PIDR-7M-ST

Report Overview
Key Players
Table of Contents
Table
Figures

The table below presents the key metrics for age-related macular degeneration (AMD) in the seven major pharmaceutical markets (7MM) covered in this report—the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan—during the forecast period from 2024–34.

In 2024, GlobalData estimated the total AMD market to be valued at $7.8 billion across the 7MM, with the US accounting for 67.2% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain, and UK) accounted for 28.9% of the global AMD market with an estimated value of $2.2 billion, and Japan’s AMD market was estimated to be $298.0 million in 2024, accounting for 3.8% of the market.
Over the forecast period, the AMD market is anticipated to grow to a value of $20.5 billion in 2034, with the US anticipated to account for 65.7% of the global market and a market value of $13.5 billion. The US market is anticipated grow at a CAGR of 10.0%, while the 5EU market is anticipated to grow at a CAGR of 10.9% to reach a market value of $6.3 billion in 2034. Japan is anticipated to witness the slowest growth among the 7MM with a CAGR of 8.9% during the forecast period and a market value of $702.1 billion in 2034.
Major drivers of growth in the AMD market during the forecast period include the following –
• The launches of longer-acting anti-vascular endothelial growth factor (VEGF) therapies to treat patients with wet AMD (wAMD) and tyrosine kinase inhibitor (TKI) therapies
• The availability of therapies for geographic atrophy (GA), which will increase the number of treatable cases of AMD
• The launch of the first pharmacotherapy exclusively for early AMD, which will increase treatment options available for many patients with this sub-indication
Major barriers to growth in the AMD market during the forecast period will include the following:
• Increased pressure to provide evidence of drug cost-effectiveness in the 7MM, which could complicate the reimbursement process of late-stage pipeline agents
• The high annual cost of therapy (ACOT) of cell and gene therapies that are anticipated to launch within the forecast period and may cause payers to favor cheaper alternatives
• Products that are due to lose exclusivity within the forecast period, and the subsequent launch of biosimilars

Scope

Overview of AMD, including epidemiology, symptoms, diagnosis, and disease management.

Annualized AMD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the AMD therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AMD treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global AMD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Report deliverables include a Word report and an Excel-based forecast model

Forecast includes the 7 major markets (7MM)

Forecast covers the period 2021-2031.

2021 base year sales within the AMD market are approximately $7.4 billion across the 7MM detailed in this report. GlobalData estimates that the AMD market will grow at a compound annual growth rate (CAGR) of 14.1% to reach $27.5 billion by the end of the forecast period.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM AMD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM AMD therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

4D Molecular Therapeutics
AbbVie
Adverum Biotechnologies
AiViVa BioPharma
Alkeus Pharmaceuticals
Allegro Opthalmics
Annexon
Apellis
Ashvattha Therapeutics
Astellas
Aviceda Therapeutics
Bausch & Lomb
Bayer
Belite Bio
Boehringer Ingelheim
CHEPLAPHARM
Chugai
Clearside Biomedical
EyePoint Pharmaceuticals
Genentech
Guangzhou Yinming Biomedical Technology Co Ltd
Kodiak Sciences
Luxa Biotechnology
Merck
Novartis
Ocugen
Ocular Therapeutix
Outlook Therapeutics
QLT Inc
Regeneron
REGENEXBIO
Roche
Santen
Stealth BioTherapeutics
Sylentis

List of Contents

List of Tables

List of Figures

1 Age-Related Macular Degeneration: Executive Summary

1.1 AMD market will grow significantly during the forecast period, reaching sales of $20.5 billion in 2034

1.2 Development of cell-based and gene therapies represent a new paradigm for AMD

1.3 Reducing treatment burden is an important unmet need for wet AMD

1.4 Treatment for geographic atrophy and dry AMD represent an important unmet need for AMD

1.5 Late-stage pipeline therapies are anticipated to drive growth in the AMD market

1.6 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Overview

3.1.2 Etiology

3.1.3 Pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed incident cases of AMD

4.4.4 Forecast assumptions and methods: total prevalent cases of AMD

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD

4.5 Epidemiological forecast for AMD (2024–34)

4.5.1 Diagnosed incident cases of AMD

4.5.2 Age-specific diagnosed incident cases of AMD

4.5.3 Sex-specific diagnosed incident cases of AMD

4.5.4 Diagnosed incident cases of early AMD

4.5.5 Diagnosed incident cases of late AMD

4.5.6 Diagnosed incident cases of late dry AMD

4.5.7 Diagnosed incident cases of wet AMD

4.5.8 Total prevalent cases of AMD

4.5.9 Age-specific total prevalent cases of AMD

4.5.10 Sex-specific total prevalent cases of AMD

4.5.11 Total prevalent cases of early AMD

4.5.12 Total prevalent cases of late AMD

4.5.13 Total prevalent cases of late dry AMD

4.5.14 Total prevalent cases of wet AMD

4.5.15 Diagnosed prevalent cases of AMD

4.5.16 Age-specific diagnosed prevalent cases of AMD

4.5.17 Sex-specific diagnosed prevalent cases of AMD

4.5.18 Diagnosed prevalent cases of early AMD

4.5.19 Diagnosed prevalent cases of late AMD

4.5.20 Diagnosed prevalent cases of late dry AMD

4.5.21 Diagnosed prevalent cases of wet AMD

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Longer treatment duration

7.3 Treatment for GA

7.4 Fibrosis prevention

7.5 Patient and healthcare system burden

8 R&D Strategies

8.1 Overview

8.1.1 Focus on the development of longer-acting therapies

8.1.2 Diversifying into cell and gene therapies for AMD

8.1.3 Development of novel mechanisms for AMD

8.2 Clinical trials design

8.2.1 Consideration of endpoints for the whole spectrum of AMD

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Reviewers

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Table

Table 1: AMD: key metrics in the 7MM

Table 2: Biological pathways associated with AMD risk genes

Table 3: The four-stage AREDS classification of AMD

Table 4: Symptoms of AMD

Table 3: Risk factors and comorbid conditions associated with AMD

Table 6: Treatment guidelines for AMD

Table 7: Top 10 deals by value, 2020–25

Table 8: AMD market – global drivers and barriers, 2024–34

Table 9: Key events impacting sales for AMD in the US, 2024–34

Table 10: AMD market – drivers and barriers in the US, 2024–34

Table 11: Key events impacting sales for AMD in the 5EU, 2024–34

Table 12: AMD market – drivers and barriers in the 5EU, 2024–34

Table 13: Key events impacting sales for AMD in Japan, 2024–34

Table 14: AMD market – drivers and barriers in Japan, 2024–34

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for AMD in 2024 and 2034

Figure 2: Analysis of the company portfolio gap in AMD during the forecast period

Figure 3: Competitive assessment of late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period

Figure 4: Comparison of the eye under normal vision and severe vision loss due to AMD

Figure 4: 7MM, diagnosed incidence of AMD, both sexes, ages ≥50 years, cases per 100,000 population, 2024

Figure 5: 7MM, total prevalence of AMD, both sexes, ages ≥50 years, %, 2024

Figure 6: 7MM, diagnosed prevalence of AMD, both sexes, ages ≥50 years, 2024

Figure 7: 7MM, sources used and not used to forecast the diagnosed incident cases of AMD, early AMD, late AMD, late dAMD, and wAMD

Figure 8: 7MM, sources used and not used to forecast the total prevalent cases of AMD, early AMD, late AMD, late dAMD, and wAMD

Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of AMD, early AMD, late AMD, late dAMD, and wAMD

Figure 10: 7MM, diagnosed incident cases of AMD, N, both sexes, ages ≥50 years, 2024

Figure 11: 7MM, age-specific diagnosed incident cases of AMD, both sexes, N, ages ≥50 years, 2024

Figure 12: 7MM, sex-specific diagnosed incident cases of AMD, N, ages ≥50 years, 2024

Figure 13: 7MM, diagnosed incident cases of early AMD, N, both sexes, ages ≥50 years, 2024

Figure 14: 7MM, diagnosed incident cases of late AMD, N, both sexes, ages ≥50 years, 2024

Figure 15: 7MM, diagnosed incident cases of late dAMD, N, both sexes, ages ≥50 years, 2024

Figure 16: 7MM, diagnosed incident cases of wAMD, N, both sexes, ages ≥50 years, 2024

Figure 17: 7MM, total prevalent cases of AMD, both sexes, ages ≥50 years, N, 2024

Figure 18: 7MM, age-specific total prevalent cases of AMD, both sexes, N, ages ≥50 years, 2024

Figure 19: 7MM, sex-specific total prevalent cases of AMD, N, ages ≥50 years, 2024

Figure 20: 7MM, total prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2024

Figure 21: 7MM, total prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2024

Figure 22: 7MM, total prevalent cases of late dAMD, both sexes, ages ≥50 years, N, 2024

Figure 23: 7MM, total prevalent cases of wAMD, both sexes, ages ≥50 years, N, 2024

Figure 24: 7MM, diagnosed prevalent cases of AMD, both sexes, ages ≥50 years, N, 2024

Figure 25: 7MM, age-specific diagnosed prevalent cases of AMD, both sexes, N, ages ≥50 years, 2024

Figure 26: 7MM, sex-specific diagnosed prevalent cases of AMD, N, ages ≥50 years, 2024

Figure 27: 7MM, diagnosed prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2024

Figure 28: 7MM, diagnosed prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2024

Figure 29: 7MM, diagnosed prevalent cases of late dAMD, both sexes, ages ≥50 years, N, 2024

Figure 30: 7MM, diagnosed prevalent cases of wAMD, both sexes, ages ≥50 years, N, 2024

Figure 23: Amsler grid, as viewed by patients with normal vision and with wAMD

Figure 24: Unmet needs and opportunities in AMD

Figure 25: Overview of the development pipeline in AMD

Figure 26: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for AMD in the 7MM during the forecast period

Figure 27: Competitive assessment of late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period

Figure 28: Competitive assessment of the wAMD pipeline drugs benchmarked against the standard of care, Eylea, and GA pipeline drugs benchmarked against the standard of care, Izervay

Figure 29: Analysis of the company portfolio gap in AMD during the forecast period

Figure 30: Global (7MM) sales forecast by country for AMD in 2024 and 2034

Figure 31: Sales forecast by disease subtype for AMD in the US in 2034

Figure 32: Sales forecast for GA in the US in in 2024 and 2034

Figure 33: Sales forecast by class for wAMD in the US in 2024 and 2034

Figure 34: Sales forecast by disease subtype in the 5EU in 2034

Figure 35: Sales forecast by class for wAMD in the 5EU in 2024 and 2034

Figure 36: Sales forecast by class for wAMD in Japan in 2024 and 2034

Age-Related Macular Degeneration Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Age-Related Macular Degeneration Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Age Related Macular Degeneration reports

Pharmaceuticals

New

Q1 2026 CRO Activity and Intel Report

Pharmaceuticals

New

Bio/Pharmaceutical Outsourcing Report, April 2026

Pharmaceuticals

New

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global…

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Age-Related Macular Degeneration Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 in real time.

Access a live Age-Related Macular Degeneration Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Age-Related Macular Degeneration Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

Scope

Key Highlights

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports